Open Access. Powered by Scholars. Published by Universities.®

Biochemistry, Biophysics, and Structural Biology Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 2 of 2

Full-Text Articles in Biochemistry, Biophysics, and Structural Biology

Preclinical Single-Dose Safety And Pharmacokinetic Evaluation Of Fluorocoxib A: Pilot Study Of Novel Cyclooxygenase-2-Targeted Optical Imaging Agent In A Canine Model, Maria Cekanova, M Uddin, Alfred Legendre, Gina Gaylon, Joseph Bartges, Amanda Callens, L Marnett May 2013

Preclinical Single-Dose Safety And Pharmacokinetic Evaluation Of Fluorocoxib A: Pilot Study Of Novel Cyclooxygenase-2-Targeted Optical Imaging Agent In A Canine Model, Maria Cekanova, M Uddin, Alfred Legendre, Gina Gaylon, Joseph Bartges, Amanda Callens, L Marnett

Alfred M Legendre DVM, MS, DACVIM

We evaluated preclinical single-dose safety, pharmacokinetic properties, and specific uptake of the new optical imaging agent fluorocoxib A in dogs. Fluorocoxib A, N-[(5-carboxy-X-rhodaminyl)but-4-yl]-2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetamide, selectively binds and inhibits the cyclooxygenase-2 (COX-2) enzyme, which is overexpressed in many cancers. Safety pilot studies were performed in research dogs following intravenous (i.v.) administration of 0.1 and 1  mg/kg fluorocoxib A. Blood and urine samples collected three days after administration of each dose of fluorocoxib A revealed no evidence of toxicity, and no clinically relevant adverse events were noted on physical examination of exposed dogs ...


Preclinical Single-Dose Safety And Pharmacokinetic Evaluation Of Fluorocoxib A: Pilot Study Of Novel Cyclooxygenase-2-Targeted Optical Imaging Agent In A Canine Model, Maria Cekanova, M Uddin, Alfred Legendre, Gina Gaylon, Joseph Bartges, Amanda Callens, L Marnett Oct 2012

Preclinical Single-Dose Safety And Pharmacokinetic Evaluation Of Fluorocoxib A: Pilot Study Of Novel Cyclooxygenase-2-Targeted Optical Imaging Agent In A Canine Model, Maria Cekanova, M Uddin, Alfred Legendre, Gina Gaylon, Joseph Bartges, Amanda Callens, L Marnett

Maria Cekanova MS, RNDr, PhD

We evaluated preclinical single-dose safety, pharmacokinetic properties, and specific uptake of the new optical imaging agent fluorocoxib A in dogs. Fluorocoxib A, N-[(5-carboxy-X-rhodaminyl)but-4-yl]-2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetamide, selectively binds and inhibits the cyclooxygenase-2 (COX-2) enzyme, which is overexpressed in many cancers. Safety pilot studies were performed in research dogs following intravenous (i.v.) administration of 0.1 and 1  mg/kg fluorocoxib A. Blood and urine samples collected three days after administration of each dose of fluorocoxib A revealed no evidence of toxicity, and no clinically relevant adverse events were noted on physical examination of exposed dogs ...